MedTrace Logo

Differences in the Eradication of Helicobacter Pylori by Different Therapies

NCT05097846 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-02-18

No results posted yet for this study

Summary

To compare the performance of four treatment regimens for radical treatment of Helicobacter pylori, evaluating the efficacy, safety, patient compliance, and socioeconomic evaluation of the four regimens. The four treatment regimens included (1) Vonoprazan Fumarate + amoxicillin + doxycycline, (2) Vonoprazan Fumarate + furazolidone + doxycycline, (3) esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline, and (4) esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Group1 Vonoprazan Fumarate + amoxicillin + doxycycline

Vonoprazan Fumarate + amoxicillin + doxycycline

DRUG

Group2 Vonoprazan Fumarate + furazolidone + doxycycline

Vonoprazan Fumarate + furazolidone + doxycycline

DRUG

Group3 esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline

esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline

DRUG

Group4 esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline

esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline

Sponsors & Collaborators

  • wang xiaoyan

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-17
Primary Completion
2022-06-17
Completion
2022-10-17

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05097846 on ClinicalTrials.gov